Serina Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
Serina Therapeutics, Inc. (SER) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate of 4.51% for the 3-month period ending 2024-06-30, per its 10-Q filed 2024-08-09.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate · last filed 2025-03-24
- Serina Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2024-06-30 was 4.51%.
- Serina Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2024-03-31 was 4.18%.
- Serina Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2023-09-30 was 4.12%.
- Serina Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2022-06-30 was 2.90%, a 192.93% increase year-over-year.
- Serina Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2023 was 0.00%, a 100.00% decline from fiscal 2022.
- Serina Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2022 was 1.74%, a 75.76% increase from fiscal 2021.
- Serina Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2021 was 0.99%, a 120.00% increase from fiscal 2020.
- Serina Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2020 was 0.45%, a 77.04% decline from fiscal 2019.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month as first filed |
|---|---|---|---|---|---|
| 2024-06-30 | 4.51% 10-Q · filed 2024-08-09 | 4.47% 10-Q · filed 2024-08-09 | |||
| 2024-03-31 | 4.18% 10-Q · filed 2024-05-14 | ||||
| 2023-12-31 | 0.00% 10-K · filed 2025-03-24 | 4.12% 10-K · filed 2024-03-22 | |||
| 2023-09-30 | 4.12% 10-Q · filed 2023-11-14 | 4.12% 10-Q · filed 2023-11-14 | |||
| 2022-12-31 | 1.74% 10-K · filed 2024-03-22 | ||||
| 2022-09-30 | 1.74% 10-Q · filed 2023-11-14 | ||||
| 2022-06-30 | 2.90% 10-Q · filed 2023-08-14 | 1.74% 10-Q · filed 2023-08-14 | |||
| 2022-03-31 | 1.62% 10-Q · filed 2023-05-12 | ||||
| 2021-12-31 | 0.99% 10-K · filed 2023-03-31 | ||||
| 2021-09-30 | 0.99% 10-Q · filed 2022-11-10 | ||||
| 2021-06-30 | 0.99% 10-Q · filed 2022-08-12 | 0.99% 10-Q · filed 2022-08-12 | |||
| 2020-12-31 | 0.45% 10-K · filed 2022-03-29 | ||||
| 2020-09-30 | 0.00% 10-Q · filed 2020-11-16 | 0.45% 10-Q · filed 2021-11-12 | |||
| 2020-06-30 | 0.45% 10-Q · filed 2021-08-13 | 0.45% 10-Q · filed 2021-08-13 | |||
| 2019-12-31 | 1.96% 10-K · filed 2021-03-31 | ||||
| 2019-09-30 | 1.68% 10-Q · filed 2020-11-16 | 2.41% 10-Q · filed 2020-11-16 | |||
| 2019-06-30 | 0.00% 10-Q · filed 2020-08-14 | 2.44% 10-Q · filed 2020-08-14 | |||
| 2019-03-31 | 2.44% 10-Q · filed 2020-05-14 | ||||
| 2018-12-31 | 2.99% 10-K/A · filed 2020-03-31 | ||||
| 2018-09-30 | 2.75% 10-Q · filed 2019-11-14 | 2.71% 10-Q · filed 2019-11-14 | |||
| 2018-06-30 | 2.74% 10-Q · filed 2019-08-14 | 2.68% 10-Q · filed 2019-08-14 | |||
| 2018-03-31 | 2.67% 10-Q · filed 2019-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| TALPHERA, INC. (TLPH) | United States | $0.060B |